RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pacira Biosciences Stock

Pacira Biosciences Equity 2024

Pacira Biosciences Equity

870.13 M USD

Ticker

PCRX

ISIN

US6951271005

WKN

A1H68T

In 2024, Pacira Biosciences's equity was 870.13 M USD, a 12.27% increase from the 775 M USD equity in the previous year.

Pacira Biosciences Aktienanalyse

What does Pacira Biosciences do?

Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for use in anesthesia, pain management, and oncology. The company was founded in 2007 and is headquartered in Parsippany, New Jersey. Pacira Biosciences' success story began with the development of EXPAREL, a long-acting painkiller based on liposome technology. EXPAREL was the first product approved by the US Food and Drug Administration (FDA) for local infiltration to relieve pain after surgery. Since then, the company has expanded its portfolio and now offers products for use in oncology and other areas of medicine. Pacira Biosciences' business model is based on the manufacture and sale of high-quality, innovative drugs both in the US and internationally. Product development is done in close collaboration with doctors and patients to ensure that patient needs are met and medical requirements are fulfilled. The company operates in three main divisions: anesthesia, pain management, and oncology. In the anesthesia division, Pacira Biosciences offers the product EXPAREL, which is used for local infiltration into the surgical wound to relieve pain after surgery. EXPAREL is a liposomal, slow-release painkiller that enables patients to recover without pain and minimizes the risk of opioid dependence. In the pain management division, Pacira Biosciences has developed the products bupivacaine and meloxicam, which are used in the treatment of acute and chronic pain. These products provide a safe and effective alternative to opioids for pain management. In the oncology division, the company has introduced the product ONIVYDE, which is used for the treatment of patients with metastatic pancreatic cancer. ONIVYDE was developed in collaboration with the FDA and has proven to be effective in combating cancer. In addition to offering products, Pacira Biosciences works closely with doctors, hospitals, and government agencies to ensure that the products are used safely and effectively. The company also conducts extensive research and development activities to develop new products and improve existing ones. In conclusion, Pacira Biosciences Inc. is a leading international company specializing in innovative pharmaceuticals in the fields of anesthesia, pain management, and oncology. The company is actively working on developing new innovative products and offering doctors and patients a safe and effective alternative to traditional pain medications. With its strong commitment to the healthcare industry, Expard will continue to advance the development of new and therapeutic agents to better assist patients. Answer: Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for anesthesia, pain management, and oncology. They are known for their product EXPAREL, a long-acting painkiller approved by the FDA for local infiltration after surgery. The company operates in three divisions and works closely with healthcare professionals and government agencies to ensure safe and effective use of their products. They are committed to advancing healthcare through research and development. Pacira Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Pacira Biosciences's Equity

Pacira Biosciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Pacira Biosciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Pacira Biosciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Pacira Biosciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Pacira Biosciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Pacira Biosciences stock

What is the equity of Pacira Biosciences this year?

Pacira Biosciences has equity of 870.13 M USD this year.

What was the equity of Pacira Biosciences compared to the previous year?

The equity of Pacira Biosciences has increased/decreased by 12.27% increased compared to the previous year.

What impact does a high equity have on investors of Pacira Biosciences?

A high equity is advantageous for investors of Pacira Biosciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Pacira Biosciences?

A low equity can be a risk for investors of Pacira Biosciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Pacira Biosciences affect the company?

An increase in equity of Pacira Biosciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Pacira Biosciences affect the company?

A reduction in equity of Pacira Biosciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Pacira Biosciences?

Some factors that can affect the equity of Pacira Biosciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Pacira Biosciences so important for investors?

The equity of Pacira Biosciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Pacira Biosciences take to change the equity?

To change equity, Pacira Biosciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Pacira Biosciences pay?

Over the past 12 months, Pacira Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacira Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacira Biosciences?

The current dividend yield of Pacira Biosciences is .

When does Pacira Biosciences pay dividends?

Pacira Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacira Biosciences?

Pacira Biosciences paid dividends every year for the past 0 years.

What is the dividend of Pacira Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacira Biosciences located?

Pacira Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacira Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacira Biosciences from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Pacira Biosciences pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Pacira Biosciences in the year 2023?

In the year 2023, Pacira Biosciences distributed 0 USD as dividends.

In which currency does Pacira Biosciences pay out the dividend?

The dividends of Pacira Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pacira Biosciences

Our stock analysis for Pacira Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacira Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.